AI, the disruptor-in-chief
FORWARD THINKING
Artificial intelligence is upending how industries function and it's coming for scientific research next.
Rene Caissie, an adjunct professor at Stanford University, wants AI to conduct research.
In 2021, he started a company, Medeloop.ai, that lets public health departments, researchers and life sciences companies pose research questions and receive answers immediately.
And, unlike many AI systems, Caissie told Ruth, the AI explains those answers by showing the data its results are based on.
'It used to be hard to do research,' he said, explaining that it takes a lot of time for researchers to get access to and organize data in order to answer basic scientific questions. Manual data analysis can also take months.
The company is now partnering with HealthVerity, a provider of real-world health data, to build up its data sources. In turn, HealthVerity will offer Medeloop's research platform to its clients. The company has worked with the Food and Drug Administration, the National Institutes of Health, and the Centers for Disease Control and Prevention in the past.
Caissie says the New York City Department of Health and Mental Hygiene is already using Medeloop's AI to run public health analyses.
Why it matters: Public health departments receive huge amounts of data on human health from a variety of sources. But prepping that information and analyzing it can be onerous. Having access to a research platform like Medeloop could give public health departments and academic medical centers much faster insight into trends and in turn enable them to respond more quickly.
How it works: Medeloop's AI is designed to think like a researcher. In a demo, Medeloop strategist John Ayers asked the bot how many people received a first-time autism diagnosis, broken down by age, race and sex, and what trends were visible with that data. He wanted the AI to only include people who had had interactions with a doctor for at least two years prior to diagnosis.
The platform returned a refined query to improve results and a suggestion for what medical codes to use to identify the right patients for inclusion in the study. It delivered a trial design that looked at a cohort of 799,560 patients with new autism diagnoses between January 2015 and December 2024.
Medeloop's AI showed that 70 percent of new autism diagnoses were for males. A monthly trends report found that, outside of a dip during the Covid-19 pandemic, new autism diagnoses have been on the rise, particularly among 5-11 year olds since 2019.
Though Medeloop doesn't determine the cause of autism, the ease with which users can obtain answers could help speed up the pace of research.
One of the platform's key innovations is its use of a federated network of data. Medeloop's new deal with HealthVerity will raise the platform's de-identified and secure patient records to 200 million.
Notably, the data never leaves the health system, which increases security. Instead, Medeloop sends its AI to wherever the data is stored, analyzes it there and then returns the results to the platform.
WELCOME TO FUTURE PULSE
This is where we explore the ideas and innovators shaping health care.
Scientists are making cover art and figures for research papers using artificial intelligence. Now illustrators are calling them out, Nature's Kamal Nahas reports.
Share any thoughts, news, tips and feedback with Danny Nguyen at dnguyen@politico.com, Carmen Paun at cpaun@politico.com, Ruth Reader at rreader@politico.com, or Erin Schumaker at eschumaker@politico.com.
Want to share a tip securely? Message us on Signal: Dannyn516.70, CarmenP.82, RuthReader.02 or ErinSchumaker.01.
TECH MAZE
Large language models like ChatGPT and Claude generate inferior mental health care treatment when presented with data about a patient's race, according to a study published this week in npj Digital Medicine.
The findings: Researchers from Cedars-Sinai, Stanford University and the Jonathan Jaques Children's Cancer Institute tested how artificial intelligence would produce diagnoses for psychiatric patient cases under three conditions: race neutral, race implied and race explicitly stated using four models.
They included the commercially available large language models ChatGPT, Claude and Gemini, as well as NewMes-15, a local model that can run on personal devices without cloud services. The researchers then asked clinical and social psychologists to evaluate the findings for bias.
Most LLMs recommended dramatically different treatments for African American patients compared with others, even when they had the same psychiatric disorder and patient profile outside of race. The LLMs also proposed inferior treatments when they were made aware of a patient's race, either explicitly or implicitly.
The biases likely come from the way LLMs are trained, the researchers wrote, and it's unclear how developers can mitigate those biases because 'traditional bias mitigation strategies that are standard practice, such as adversarial training, explainable AI methods, data augmentation and resampling may not be enough,' the researchers wrote.
Why it matters: The study is one of the first evaluations of racial bias on psychiatric diagnoses across multiple LLMs. It comes as people increasingly turn to chatbots like ChatGPT for mental health advice and medical diagnoses.
The results underscore the nascent technology's flaws.
What's next: The study was small — only 10 cases were examined — which might not fully capture the consistency or extent of bias. The authors suggest that future studies could focus on a single condition with more cases for deeper analysis.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Omada Health IPO signals healthier market, avoids 'down-round' trend
The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first trading day on Friday at $23 a share, a 21% jump from the IPO price of $19. The IPO valued the company just above $1 billion (excluding employee options), a figure that's nearly identical to Omada's last private valuation of $1 billion set in its previous VC round. The debut is one of the first among recent IPOs that was not a so-called down-round. Many of the latest public listings, including Hinge, ServiceTitan, and Reddit, priced below their private market highs, though have faired well as public companies. For founder and CEO Sean Duffy, the successful public offering validates his decision to start a company that he believed the market desperately needed. In 2011, he dropped out of Harvard Medical School after realizing that chronic illness patients required more continuous support than the existing healthcare system delivered. Before the offering, he owned 4.1% of the company, according to Omada's offering document. Other significant shareholders included Revelation Partners (10.9%), US Venture Partners (9.9%), Andreessen Horowitz (9.6%), and FMR (9.3%). Duffy told TechCrunch that over his 14-year journey as a founder, he had many harrowing moments. "I didn't think our series A was going to come together because we were working on this commercial deal that didn't materialize, and that spooked one investor," he said. "As a young business, something tries to kill you every month," he continued. "And then as the business grows, it turns into like every quarter or six months, year, two years." One of the recent challenges for many digital health businesses is navigating the "collapse" of the market post-COVID boom. Omada steered through the turbulent times by seeking new, rising markets. It recently expanded its offerings to include diet management support for GLP-1 patients.
Yahoo
8 hours ago
- Yahoo
Migratory birds develop antibodies to bird flu, officials say
(WAVY) – Wildlife officials are keeping a close eye on the spread of avian influenza after along the North Carolina coast earlier this year — most of them brown pelicans. The outbreak has since been linked to the H5N1 strain of bird flu, a virus that continues to mutate and occasionally jump to other species, raising concern among experts. Miranda Turner, a wildlife health biologist with the North Carolina Wildlife Resources Commission, said the area is a prime wintering ground for birds — making it easier for disease to spread. 'When you bring a lot of animals together and you have them traveling from different locations, it's a really good way to transmit diseases,' Turner said. In Hampton Roads, bird flu outbreaks aren't new. Lisa Barlow, president of T recalls treating sick and dying Canada geese during a 2021 outbreak on the Lafayette River. 'We dealt with about three to four dozen Canada geese that came in sick and dying,' Barlow said. 'Only six survived the flu, and even those had to be euthanized due to severe neurological symptoms.' Barlow described birds arriving unable to hold their heads up, their beaks caked in mud. Many died within 24 hours. As the virus continues to affect wildlife, it's not just birds at risk. , including seals, cats and even cattle. Experts say it's mutated at least several times since it was first identified. 'I mean, anything that can do that — it's kind of frightening, but amazing,' Barlow said. Despite the concerning spread, health officials emphasize the risk to humans remains low. According to the Centers for Disease Control and Prevention, 70 human cases have been reported nationwide, including one death. Most infections have been among people with repeated exposure to infected animals, such as poultry or dairy farm workers. 'There's really low risk,' Turner said. 'Still, it's a good idea to clean bird feeders regularly and wear gloves or a mask if you handle injured wildlife.' Barlow also urges caution for those who come across sick birds. 'If you do want to help, wear gloves, protect yourself,' she said. 'Common sense goes a long way.' Meanwhile, as migratory birds continue to interact and spread the virus, some are developing natural antibodies, according to Turner. 'They're bouncing back and creating herd immunity,' she said. Last week, the Associated Press reported the in funding meant to support Moderna's development of a bird flu vaccine. The vaccine, which uses mRNA technology similar to the COVID-19 vaccine, had shown early promise in clinical trials. For now, wildlife officials say they expect to see more outbreaks in the years ahead, especially during peak migration periods. 'Because this virus is so common in migratory birds, it is likely that we will continue to see cases here and there every winter,' Turner said. As of right now, there have been no confirmed human cases of H5N1 in Virginia and although the risk remains low for humans, for birds it can be extremely deadly – leading to large die-off events like the ones we saw near Cape Hatteras. 'Unfortunately, this was the first kind of major large scale mortality event… while it looks really bad at that small scale of seeing 300 brown pelicans die – it's not impacting their population as a whole or the species as a whole,' adds Turner. Turner also explains that the surviving pelicans are still there, 'The brown pelicans that did survive that event were still nesting on that island successfully and are doing well. So really, it's a short scale kind of scary looking event, but nothing that raises alarm for biologists in the long term.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
9 hours ago
- Yahoo
New coronavirus discovered in China ‘only small step' from infecting humans
A new coronavirus discovered in China is only a small step from mutating and causing another global pandemic, experts have warned. Scientists believe the variant, called HKU5-CoV-2, may infect a broader range of animals than Covid-19 – which caused millions of deaths – and may have more potential for jumping between species. US researchers fear that HKU5-CoV-2, found in China, in February, could also infect humans, leading to a widespread outbreak. The new study, published in Nature Communications, looked at a lesser-known group of coronaviruses called merbecoviruses, which includes HKU5 and MERS-CoV, which is responsible for the deadly Middle East Respiratory Syndrome. The team from Washington State University looked at how the new pathogen interacts with human cells. They found that a small change in the virus's spike protein could allow it to attach to human ACE2 cells in people's throats, mouths and noses. HKU5-CoV-2 can infect and replicate inside human cells in both the airways and gut. According to the World Health Organisation, about 35 per cent of people infected with Middle East Respiratory Syndrome die. Since 2012, some 27 countries have reported cases, leading to 858 known deaths due to the infection, which spread from camels. But when HKU5 was discovered in February, scientists warned against exaggerating the risks because it does not enter human cells as readily as Sars-CoV-2, which caused Covid-19. HKU5 was first detected in bats by scientists from the Chinese laboratory where some say Covid originated in 2019. Prof Michael Letko, a virologist who co-led the study, said: 'HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. 'What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans.' When Covid-19 emerged it was widely blamed on markets in China where different breeds of wild animal are kept caged and often slaughtered close to other animals. Meat is sold at the open-air stalls. Critics said the markets were the perfect breeding ground for new zoonotic diseases – those that spread to humans – to emerge. The scientists, whose experiments studied how the new pathogen interacts with human cells, believe the virus would have to carry certain mutations if it were to infect humans. 'These viruses are closely related to MERS, so we have to be concerned if they ever infect humans,' Prof Letko said. 'While there's no evidence they've crossed into people yet, the potential is there and that makes them worth watching.'
